Today, we will start the stock market briefing. This is the briefing of the stock market with two pillars. I would like to introduce the two best stock experts in South Korea: Kim Young-min and Kim Jun-woo, managers from MBN Gold. Hello, it's nice to meet you.

Bad feelings always tend to become a reality, and concerns often materialize. Yesterday, we discussed Yuhan Corporation and Oscotec during our briefing, and we provided various pieces of advice. We gave two pieces of advice: for those who already hold stocks, we suggested taking some profit when there is a gap up, as this is a characteristic of the K stock market. For new investors, we advised not to get too excited when there is a gap up and to wait until the gap closes before approaching the stock. Our guidance wasn't perfect, but it was reasonably good. However, later, Oscotec's stock price fell by 11%, leading to the thought that this market is really tough.

I'm trying. It's tough in Yeongdo. I want to make a few comments about Yuhan Corporation and Oscotec. Anyway, yesterday, we had this expression in the stock market that the supply and demand are dominant. As you mentioned in the briefing earlier, regarding Yuhan Corporation's supply and demand, institutional investors, especially pension funds, sold 500,000 shares, and investment trusts sold 700,000 shares. So, while Yuhan Corporation itself had a record-breaking trading volume, good news came out, but foreign institutions sold off in large amounts. This makes many people wonder if this is a bad sign or if I am misunderstanding something. But don't doubt it; we are literally walking on an unprecedented path. Until now, no pharmaceutical or biotech company in South Korea has earned royalties based on big pharma sales.

Yesterday, the company that had been exporting received FDA approval for sales in the United States. However, since Yuhan Corporation has not yet received any royalties from sales, let's consider Samsung Biologics. They have been making significant investments in facilities to increase their production capacity, and as they start to improve their performance by providing biopharmaceuticals to global big pharma, their stock price could rise to 700,000, 800,000, or even 900,000 won. 

Yuhan Corporation had already seen some expectations reflected in their stock price regarding new drug development. With the recent news of the approval, there was hope that the stock price would surpass 110,000 won. It would have been less disappointing if it had broken through that level, but it came very close to 110,000 won and then...

The adjustment has just begun. The value of Yuhan Corporation, which you are all familiar with, has already been somewhat reflected in the stock price. The factors that can elevate its future value ultimately depend on how effectively Johnson & Johnson can market and increase prescriptions for the combination therapy of Lecabazepine and Livratan. I view this quite positively. Additionally, the timeline is not over; there is the World Lung Cancer Conference in September, and there are still approval issues in Europe and Japan. Therefore, if the outlook for performance changes to one of confidence, the stock prices of Yuhan Corporation and Osco Tech, which have achieved success, will also have ample opportunity to rise.

Can we recover a bit? Well, yesterday was literally a vertical flow. You can understand it like this. I have prepared an investment strategy for Oscotec, and Manager Juno, it's not just Oscotec led by Yoo Han; when bank stocks suddenly look good, individuals are trying to rotate. However, the financial authorities are now introducing policies for coexistence in society. Cosmetics are all good, but if there’s even a slight misstep, there’s no forgiveness. That's right, why is this happening? Looking at the power infrastructure stocks, especially with yesterday’s upper shadows, I really don't know what to do. Cosmetics and power infrastructure stocks have recently shown good performance, and they have been relatively strong compared to the recent market, but recently, some profit-taking has emerged.

Starting off, the downward trend has been quite significant, making trading extremely challenging. Furthermore, in the power infrastructure sector, the stock prices have recently been moving similarly to those of AI semiconductors, which can be said to be following the trend of Nvidia. However, during after-hours trading yesterday, companies in the power industry, like Jeong Electric, saw a considerable rise. This was primarily due to announcements regarding the reconstruction of Ukraine, where the power industry is expected to support the development of power and communication infrastructure worth 650 trillion won. As a result, power-related stocks have been active. Additionally, there seems to be some anticipation regarding the performance of cosmetics companies, which may not have been fully reflected yet. Yesterday, there were also developments in exports.

Data has now surged more than 18% compared to the previous month. Therefore, in the cosmetics sector, rather than all companies rising together as before, we need to focus on those that are showing substantial growth, particularly those with outstanding sales in the U.S. Last night, there was also positive news that the U.S. power infrastructure has increased by more than 80% compared to the same period last year. In this context, companies related to U.S. power infrastructure, as well as those in the cosmetics sector and power-related companies, including those involved in power generation or supplying electrical equipment and cables, are likely to survive. So, after Nvidia's earnings announcement on the 28th of next week, if uncertainty is resolved, there could be a strong buying trend in the power infrastructure sector.

I'm wondering if there won't be an influx; rather, if there's a correction, this week could be seen as a point of correction from a perspective of quantity. I'm observing this. Manager Kim Joon is saying that the power infrastructure should move along with NVIDIA's performance. However, NVIDIA's stock price is almost fixed right now. Therefore, the power infrastructure should also come in at that level, but K power isn't coming in. Today, there's also a limited amount of Oscotec as a stock, but there are really many people who are very concerned about the cosmetics power infrastructure. Yes, that's the nature of the market. So, when pregnant individuals are reaching a conclusion, there are even pieces of advice suggesting that they should not invest in the market. This is quite frustrating. Let's move on from that. Our Americano also thinks that there are no new issues in cosmetics and sees it as a psychological high point. You're aware of the market, right? It needs a little more support, but the indicators are starting to show a slight downturn.

그런 부분들이 아마도 이게 기대치가 말씀해주신 것처럼 너무 높잖아요. 지금, 그런데 이제 그 높은 기대치를 계속 충족시키는 기업은 전 세계에서 딱 하나밖에 없어요. 비디아. 나머지 기업들은 그 높은 기대치를 충족을 못 시키기 때문에 지금 전부 다 데이터들이 발표될 때마다 약간 심리가 조금 꺾이고 있는 그런 상황이기 때문에, 우리 뭐 오늘 계속 말씀해주신 것처럼 세론, 뭐 이런 것들 말씀해 주시지만 실제로 이제 주가라는 건 항상 모든 우리가 알고 있는 호재나 어떤 기대치가 먼저 반영되어 있다는 점을 앞으로 주가 움직임을 우리가 좀 따져봐야 한다고 조언하고 싶습니다. 좋아요, 그래서 오늘의 일발 장전의 일발 종목 중요합니다. 세론, 선반영해 전 세계 최고입니다. 자, 영민 매니, 오늘의 일발 종목은 뭘로 우리가 승부를 봐요? 오늘, 그래서 제가 이제...

Should I focus on semiconductors, or should I shift to pharmaceuticals and biotechnology? While looking at various sectors, there is still a debate about whether the U.S. economy is doing well or poorly. Today, as mentioned earlier, the bond market was really volatile; it was quite chaotic. The employment data from last April to this March has been revised, and over 810,000 jobs were adjusted downward. So, does that mean the U.S. employment figures were inflated? One could argue that, and on the other hand, it suggests that employment wasn't really that strong, which could lead to further interest rate hikes. This has ultimately led to a conclusion. The elements causing this volatility in the U.S. market, particularly in the bond market, were also made public in the FMC meeting today.

Most members of the Federal Reserve confirmed that there were indeed advocates for a rate cut back in July, which suggests a rather dovish stance. It seems that the argument for lowering interest rates is gaining some traction. On the other hand, consumer spending in the United States is currently quite robust. Today, shares of the retail company Target surged by 11%. Meanwhile, the department store Macy's also saw its stock rise by more than 12%. Additionally, if you look at Walmart's stock price, it is performing at an all-time high, far surpassing that of South Korea's Emart. The stock of the e-commerce company eBay is also doing very well. Therefore, companies related to consumer spending, as well as those in the e-commerce sector, are showing positive trends. I also mentioned recently that we should observe the spread of robotics and AI in this context.

Today, I would like to introduce a company called Cafe 24. Cafe 24 is a platform that allows you to create online stores, which we typically refer to as cafes in the online space, not to be confused with the physical coffee shops we visit offline. This company specializes in building e-commerce platforms, which are online storefronts. You can think of Cafe 24 as a company that provides electronic commerce solutions that integrate with businesses like Coupang, Naver, Amazon, and Japan's Rakuten. 

Recently, the stock price of Cafe 24 has shown significant movement due to a major opportunity related to YouTube Shopping, which is integrated with Google and YouTube.

Since May, the stock prices have risen sharply, but they have been somewhat stagnant since July. Considering the previous increase, I think the recent stock trend has been quite stable. After Alphabet's earnings report, there was a lot of controversy. In a way, this can be seen as a warning message about the AI industry. Following the earnings report, the CEO made some expressions that were misunderstood, leading to market reactions like, We invest so much, but when will we make money? This sentiment caused a correction in semiconductor and big tech companies, which then connected to the carry trade around August 5th.

There was a crash, but in fact, Alphabet is now focusing on the biggest business area that will carry the future, which is the live shopping sector utilizing the YouTube platform. Live shopping is now being combined with artificial intelligence. Nowadays, we used to watch home shopping channels on TV, but major home shopping companies all have separate live shopping channels. This is because shopping hosts sell products on TV, but at the same time, another host is selling different products on online channels. Therefore, the distribution channels are diversifying, and with the use of artificial intelligence, the utilization of these channels is being enhanced, leading to this kind of approach.

YouTube essentially survives on advertising. They are now dreaming of a business model where they not only promote ads but also sell products themselves. This is why the collaboration with Cafe24 regarding shopping live has come to the forefront, and Cafe24 has launched a dedicated YouTube shopping store. Because of this anticipation, the stock price saw a significant surge in May and June. I have prepared a photo for you. There is an app called TikTok, which is very disliked by the U.S. government. TikTok has a massive user base worldwide, and as you can see, it promotes products by broadcasting live on its TikTok Live page.

We often talk about hidden advertising these days. Influencers play a role similar to product placement in broadcasts, subtly promoting products either directly or indirectly. They openly promote products on live channels, displaying a purchase button that, when clicked, shows product details and connects directly to the purchasing page. It's incredibly convenient. For instance, while watching a broadcast, if an influencer presents a product that catches my interest, I can simply click a button to purchase it right away. This system is already in place. So, in the future, YouTube Shopping Live will also adopt this kind of channel, similar to Cafe 24, which is currently available on Cafe 24.

If you look at the newly launched YouTube shopping page, there is an additional step that needs to be taken. There is a procedure for signing up through a certain pathway, so currently, there hasn't been explosive sales growth. However, I believe that if we change it into a platform where business is possible like TikTok, the performance growth could become quite steep. Recently, looking at the spread of supply and demand, I see that in the AI field, particularly in semiconductors and AI medical devices, I talked about AI solutions related to robots yesterday, and today, I think we should pay attention to the integration of AI commerce. Therefore, the collaboration between Google and Cafe24, as well as the anticipation surrounding YouTube shopping live, reflects a stock that has potential.

Now, I think you can see it. In the second quarter, we recorded an operating profit of about 69 billion won, with a performance of 758 billion won, which is the best result in the last two years on a quarterly basis. Many people think that consumer goods companies and retail-related businesses are not performing well, but as I mentioned earlier, companies like Walmart and Target in the U.S. are currently showing very good results. Therefore, I believe we should also look positively at Cafe 24's performance. 

If we look at the stock price movement, it looks very good. After a strong rise in May and June, the recent market has been quite volatile. Compared to the peak, we are currently in a correction phase of about 20%, but it is in a range between 30,000 won and 40,000 won.

As it goes through the process of digesting inventory in a sideways movement within the box range, if you had bought around the early 30,000 won mark, it would have been much better. After the sharp decline on August 5th, there has been some rebound, so we are currently in a slight correction phase. If I suggest a buying price, it would be around 33,000 to 35,000 won. You might want to consider buying during this correction and aim for the previous high of around 40,000 won. Therefore, I would set the first target price at about 40,000 won and the stop-loss at around 31,000 won as a price strategy. Now, regarding Cafe 24, it is simply a discussion about startup solutions, and you can understand that the startup pertains to online e-commerce.

The points are good. First, with Google entering the shopping market, it has drawn attention away from Naver Shopping. If shopping becomes popular, there will be a significant demand, and to enter that market, one needs to go through Cafe24. That's one point. 

The second point is a bit frustrating; we've been discussing this for a year now. When we say that AI can't make money or extract value, we are currently looking for ways to integrate AI services. Because if we incorporate AI into shopping, it could be tremendous. We could even change the role of the shopping host entirely. Additionally, there are numerous analyses, right? Big data can play the role of a human shopping host. That's right. If there are delays in big data analysis or payment processing, adding AI here could create growth potential. So, I think it would be beneficial to approach Cafe24 with these two points in mind. 

As for the points to attach to the Juno manager, it's essentially about Cafe24.

The only competitor to Cafe 24 is Cafe 24 itself. Since you mentioned Google, I will talk about Apple. I would like to pick LG Innotek, which is the biggest beneficiary of Apple and has the potential to rise significantly. This is because the iPhone 16 is set to be released next month. In the second quarter, the initial shipment volume has already shown an increase in operating profit of nearly 720% compared to last year's iPhone 15. Therefore, we are anticipating record-breaking sales this time. Naturally, the demand for LG Innotek's camera modules is bound to surge. In fact, about 80% of LG Innotek's sales come from the iPhone. So, when the iPhone sells well, LG Innotek's stock price will also inevitably rise. Given the current market volatility and the fast-paced cycles, there are many factors to consider.

Those who are feeling unwell may find that simply holding an LG Notek will bring a bright smile by the second half of this year. Additionally, there is the anticipation of the iPhone release in September, and in October, we are looking forward to the unveiling of the RoboTaxi. For the first time, Zeno Tech will supply Tesla with an automotive camera mode, and in addition to the Cybertruck, various models in the lineup are now being equipped with Notek camera modules. Just looking at these developments, there are consecutive events in September and October. Therefore, by the end of this year, those who own a Notek are likely to wear a heavy, happy smile. From the perspective that if Google has Cafe 24, Apple and LG have their Notek, let's consider investing in this sector. In the world, there are now trivial worries about celebrities and Apple.

They say not to worry, but there is a bit of a color controversy. The case looks really pretty, so if you just use the case, you can't even tell what color it is. I think the case is so beautifully made that I haven't seen anyone carrying the phone without it. Nowadays, if you have a pretty case, it can definitely be a good alternative. Now, regarding the new iPhone 16, yes, the 16 is sturdy. The colors are actually designed to make it hard to attach anything to them. They did the same with the 14 and 15, saying there was no more innovation, but when you look at sales, they are doing really well. The 12 and 13 sold exceptionally well, and the replacement cycle has been just right. So, I expect the 16 to achieve record sales. Now, why is LG Innotek involved with Apple’s iPhone?

On-device AI is another way to make money with AI, which is why Apple has come into play. In this context, LG Innotek is preparing to compete with Cafe24. For those who prefer a solid and functional device by the end of the year, and for those who find the constantly changing daily cycles exhausting, yes, the K stock market can be frustrating. However, if you look at LG Innotek as a stable company, I believe you will be smiling brightly by the end of the year and celebrating Christmas happily. Additionally, in October, robot taxis will be launched. While Tesla might use radar or LiDAR, integrating camera technology with AI could be more effective. In this case, wouldn't SK Hynix be a better choice? I think SK is good, but LG Innotek is also promising. Yesterday, if someone felt disillusioned with the K stock market, they might want to focus on LG Innotek, take a look at the two iPhones, and also consider Tesla's robot taxi.

Look, the iPhone color controversy is covered with a case. I'm worried it might get scratched, so it's actually hard to just hold it bare. That's right. There is a company that makes iPhone cases, but I can't remember the name. They make interior products related to iPhones, but I can't recall the name. It might be helpful to keep that in mind. 

And, you probably saw this a lot yesterday and this morning, but since it has come up, let's briefly discuss it. As I mentioned earlier, isn't it too cheap right now for Osco Tech? Esquim, Yu Han-yang, and Osco Tech don't make sense at all. It's unbelievable. Also, Dong-kyung mentioned Yu Han-young's preferred stock limit, and general stocks have dropped by 15%. This kind of manipulation is really concerning, as he pointed out. What should we do about Osco Tech?

At that time, it was a bit concerning. As you mentioned during the briefing yesterday, nine or ten domestic securities firms raised their target prices, claiming that Yuhan's stock would be a huge success. However, in reality, they sold 700,000 shares in the fund and 500,000 shares in the pension fund, which understandably leads individual investors to feel betrayed. There has to be a reasonable approach to this. I believe that your thoughts are absolutely correct; it is indeed very undervalued right now. Yuhan's market capitalization is around 15 trillion won, and in the future, with the development of the SC formulation for Keytruda, the sales outlook, while uncertain, is still a significant factor. The question remains how much market share the SC formulation will capture from Keytruda, which has not yet occurred, making it uncertain. However, we can reasonably...

When estimating, even at the worst, the company will replace about 40 to 50%. This means we can expect at least 20 trillion won. If we calculate the royalties at about 3% to 5%, the amount becomes clear. Annually, we are looking at cash flow inflow of around 600 billion to 1 trillion won. The structure is exactly the same. Now, if the combination therapy of laser treatment, namely Lecraza and Liberi Art, begins to be prescribed, we aim to take more than half of Tagrisso's market share. Johnson & Johnson's target is 6 billion dollars, or 5 billion dollars when it peaks, which they expect to reach around the 5 billion dollar level. Even if we conservatively estimate an average of around 3 billion dollars, when converted to Korean won, that exceeds 4 trillion won. Adding a 10% margin or any percentage means an additional 300 to 400 billion won. This will steadily contribute to our operational revenue each year.

이익이 연간 2천억 원 정도인 회사인데, 그냥 가만히 앉아 있어도 로열티만 매년 3, 4천억 원 정도 받는다고 생각하면, 지금 7조 원 정도의 기업 가치는 결코 비싸다고 생각하지 않아요. 다만, 주가라는 것이 우리의 기대처럼 이렇게 벌어질 일을 한 번에 반영해서 20% 급등하고 상한가에 가면 좋겠지만, 이런 식으로 재료가 나오고 나서 세론이 좀 되고, 손도 좀 되고 여러 가지 논란들을 불러일으키면서 노이즈를 만들고, 또 그런 걸 뚫고 주가가 올라가는 거거든요. 최근에 엔비디아 지포스와 같은 사례를 보면, 앞으로의 현금 흐름이나 이런 명확한 흐름들을 감안한다고 하면, 그리고 재료가 제가 끝난 게 아니라, 9월 달에 폐암 학회도 있고, 리브 SC 재형 개발이 끝나고 나면 또…

There are still expectations for additional sales in this area, so even though the stock performance was quite poor yesterday, there is a possibility that it could rise again. In fact, I suggested that those who did not hold shares yesterday consider entering the market using the dip. However, those who entered yesterday and faced losses might be feeling frustrated. I believe that you can recover to your purchase price. Looking at Osco Tech, around 36,000 to 37,000 won, the chart shows that even when it plummeted on August 5th, that level served as support. Therefore, I think the price will find sufficient support. If you are buying at a low point, this range becomes a buying zone. Furthermore, looking at the target price mentioned yesterday, it was set at 50,000 won.

There are many discussions about 9,000 won and 60,000 won, but ultimately, the royalties are divided in a 60-40 ratio. The value of that division is not reflected at all, which is why OscoTech is very undervalued. Considering this trend, I believe there is a high possibility for a significant price increase. For those who waited for OscoTech yesterday, it gapped up, but it seems like many are currently down about 7%. This is because it dropped 10% in after-hours trading, resulting in a 7% loss for those who waited. Since OscoTech is also receiving royalties in a 60-40 split, they are indeed benefiting from it. Yes, that's correct. So, for those who entered the market yesterday, it might have been a bit surprising.

I think you might have been surprised, which is why there was a reversal and an unprecedented drop occurred. However, earlier this year, there was a rise of about 130% due to expectations, which may have led to some over-speculation. Now, technically speaking, since Kim Hyun-min mentioned this earlier, if we are to approach this anew, we should consider the recent 20-day moving average, which is around 34,000 won. Many individual investors seem to have a strong belief in the 20-day moving average. It appears that when the price dips below this average, there are program sell-offs. So, rather than panicking when it breaks below the 20-day moving average, it might be more prudent to wait until the selling pressure has clearly subsided before gathering positions. Yesterday, there was an excessive amount of selling pressure.

Due to the unprecedented trading volume and the appearance of a long bearish candle, a strong reversal is actually necessary for an immediate rebound from this point. However, unless that happens, some additional decline seems unavoidable. Therefore, instead of aggressively buying more just because there’s a slight rebound in the morning, it might be better to wait for more confirmation or consider a staggered approach. Regarding Oscotec and also Yuhan Corporation, they need to recover for the overall biopharmaceutical sector to show signs of improvement. The reason is that even though Oscotec and Yuhan Corporation received FD approval yesterday, they plummeted sharply, and this has affected HLB, a lung cancer treatment that had previously been rejected. As HLB's stock price adjusts downward, the negative sentiment in the overall biopharmaceutical sector worsens.

It has happened, and therefore, alternatives have recently been affected, with significant sell-offs occurring across companies developing COVID treatments. I believe that the decline of Yuhan Corporation and OscoTech needs to stabilize for overall investor sentiment regarding my investments to improve. Similarly, Yuhan Corporation saw a rise of about 16% yesterday, but it turned to decline during the trading session. Currently, Yuhan Corporation is experiencing an unprecedented trading volume, resulting in a large bearish candle, so I think it’s best to watch the situation closely. Today, there might be some buying activity in the early part of the session due to the perception of a significant accumulation, but if it shakes again, I would like to confirm support around 90,000 won before making an entry.

From the perspective of not being too bad, rather than becoming a protagonist in this issue today, it would be better to take a step back and observe. If there is sufficient adjustment and a certain degree of stabilizing, both Yuhan Corporation and Osstem Implant could be attractive in the long run. Similarly, in the case of Tizen, after successfully transferring technology, there was a period of adjustment for a while, and recently it has started to show some movement. Therefore, it is highly likely that Yuhan and Osstem will experience a similar trend, so I would suggest waiting for that adjustment.

For those holding these two stocks, there is an additional momentum. The introduction of the military law is noteworthy; this is an intravenous injection. It has received approval for the third phase of clinical trials, so if the Libri SC formulation obtains FDA sales approval within this year, it will be possible to prescribe the combination therapy of Libri SC formulation and Lecraza.

There is one piece of information: instead of an intravenous injection, there is an SC formulation for Pia. You can wait for that momentum while checking the time. Now, let's move on to Blue M Tech. The reason is that, regarding obesity, the discussions about Saxenda and Wigoo didn’t work out yesterday because of the instability with Yuhan Corporation and Osco. Even if they pass, it will be the same, as they are all affected together. Alteogen is in a similar situation, and Blue M Tech has also experienced significant fluctuations. Additionally, there was a retraction for the license, which had been previously granted. Even with a win, it is dropping like this, and if it gets retracted, it would be terrible. This seems to have led to a sell-off. Overall, the sentiment in the bio sector has been quite poor. So, regarding Blue M Tech, we mentioned in the morning before the market opened that there would be a gap.

When it suddenly rises like this, it can be a bit scary. This is because I worry that many people might follow it closely at the starting price. Usually, when I mention our buying price, if it starts off more than 5 to 6% higher after we talk about it in the early session, I think it’s better to wait rather than buy. For those who say, I have the heart of a beast, I'm okay, I believe it would be wise to approach it with a split strategy as you enter. My perspective on Blue M Tech hasn’t changed at all from yesterday to today. The stock price had a gap of about 10%, then came down, and the only thing that has made my heart uneasy is that. As I mentioned earlier, Blue M Tech is still preparing to enter the Korean market in October. They are a leading company in the domestic market related to the recent surge, and the excitement around it is still ongoing.

The obesity treatment market is projected to reach a size of 180 trillion won by 2028, and it didn't suddenly drop by 100 trillion or 90 trillion in just one day. Therefore, there is a steady upward adjustment of target stock prices. Novo Nordisk is also raising its target price. Especially since Novo Nordisk is on the verge of entering the Chinese market, it is inevitable that BlueMtech will be involved in this. My perspective is that the stock price has been quite favorable; since surpassing 1200 won, there has been a rebound buying trend. When considering this, it seems that it will be one of the most affordable options, especially since biosimilars for Saxenda will be released in the second half of this year. BlueMtech's client is Novartis, and Hanmi Pharmaceutical, which is conducting phase three clinical trials for a Korean obesity treatment, is also associated with BlueMtech.

As a customer, I ultimately have to benefit from it. Yesterday, due to some supply and demand factors, there was a gap that opened up, and some of the previously delayed parts were suppressed. The sentiment was mainly influenced by Yuhan Corporation and HMB Group. So, moving forward, I think it would be better to approach the market calmly. Before our market opens, if there is a gap of about 5% or 10% at the start, instead of rushing in all at once, it would be wise to consider a gradual approach or to wait and buy in a more measured manner. Lately, there seems to be a lack of funds; even the deposit amounts are low. Within the biotech sector, people are saying that there is nowhere else to go but Samsung Biologics. Yesterday, they parked all their investments in Samsung Biologics, creating a significant market movement. To remain in this market, one has to navigate such complexities.

We need to overcome this and come up with strategies to challenge ourselves. Manager Yang-min, there was a question today from Kim Ji-young asking about today's semiconductor situation, so let's take a look at the pricing strategy for SK Hynix. Yesterday, Morgan Stanley made some strange comments, which caused a significant drop. They mentioned that next year, AI semiconductors would peak out, which isn't great news. It seems like Morgan Stanley isn't too fond of rising stock prices lately. Recently, NVIDIA's stock has been recovering, so they might be trying to manipulate things a bit. Additionally, there was a downgrade report from BofA regarding Samsung Electronics and SK Hynix's target prices, which likely contributed to the drop of about 3-4% right from the start yesterday. Today, well...

If you look at NVIDIA's stock price, it is quite solid. All semiconductor equipment stocks have risen. You can just consider Morgan Stanley's report as just that. As I have mentioned before, when NVIDIA's stock price experienced a significant event, the analysis of the AI semiconductor industry is often approached from a traditional perspective, leading to an inability to properly evaluate NVIDIA's stock price. Especially in our country, Samsung Electronics and SK Hynix are likely to surpass the share of legacy DRAM with HBM, which is a type of DRAM. Recently, I talked about customized HBM in an article yesterday. By 2026, the HBM market size is expected to exceed 40 trillion won, and the share of HBM in the overall RAM market will surpass 50%. If that happens...

The share of legacy DRAM is expected to surpass HBM. This cycle is just beginning. DRAM has been around for over 50 years, and if you recognize that the era of HBM is approaching, then the discussions from Morgan Stanley may not align with reality. Of course, investments cannot be planned for 10 or 20 years. At some point, there will be a peak in investment, and concerns about over-investment can certainly be raised. However, this is not the time to worry about those issues. Keep that in mind. As I mentioned earlier about Hynix, using the expression from Kim Jo-mae, if you're feeling really fed up with the market and just want to park your investments until before the Christmas season, you might just want to consider Samsung Electronics.

You can just buy Hynix and go have fun. I think towards the end of the year, I will probably have a Christmas party that will be enjoyable for everyone. Regarding Hynix, there seems to be an obsession with the price of 200,000 won. Many people around me are concerned about it, asking why it can't reach 200,000 won. In such cases, it often drops to 199,000 won. Currently, it has fallen to 192,000 won. Ultimately, Manager Young-min keeps emphasizing that there is a significant paradigm shift in memory semiconductors, particularly with HBM, which has even changed its name. Therefore, it's important to look at the medium- to long-term trends regarding SK Hynix. Today, we also discussed the need to observe robotics, specifically Rainbow Robotics. Furthermore, the robots have reached around 27%, nearly 26.6%. Lately, robotics is becoming increasingly significant.

Related positive news continues to emerge, indicating that China is currently taking a leading position in the robotics sector. In the domestic premium robot vacuum market, companies like Roborock and others have practically secured the top three positions, as I mentioned earlier. Recently, a Chinese company unveiled a humanoid robot priced at 20 million won, showcasing a mass-production model. This robot is being integrated into various industries, which means that South Korea has no choice but to accelerate its efforts as well. In South Korea, Rainbow Robotics is actually the leading player in the humanoid robot field. Originally, the acquisition timing for Rainbow Robotics was set for 2029, allowing Samsung Electronics to exercise a call option. However, there are discussions about not waiting until 2029 to make the investment.

There is no need for it. Not only do we have 100 trillion in cash, but Samsung Electronics is also unable to make it into the global top 52 in generative AI. Furthermore, in the HBM sector, it is clearly lagging behind SK Hynix. As a latecomer in the AI industry, Samsung has not yet established its position while all the big tech companies are saying that the future of business lies in robotics. Given that the battleground is robotics, we should not overlook Samsung's investments and developments in this area. In this context, companies like Rainbow Robotics, which has two major shareholders, and Humanoid Robotics, which was established by a team that previously defeated a figure research team, have significant technological capabilities and hold numerous related patents. Therefore, there is no need to disregard Rainbow Robotics.

If Samsung were to fully acquire the patents related to robotics and develop its own human robot, it could rapidly secure a leading position in the market. Given that the field is still in its early stages, I believe that, in addition to the bio sector and AI semiconductors, robotics holds significant price appeal, especially with the possibility of interest rate cuts. Recently, companies like Apple have also entered the market, and BMW, Mercedes-Benz, and Hyundai have announced plans to mass-produce wearable robots in the latter half of this year. The key focus is on human robots, and while SB Tech is supplying gear reducers for wearable robots, it is clear that the supply of human robots will be much greater from this perspective.

In the context of elasticity, the most significant entity, as I mentioned earlier, has to be Rainbow Robotics. If Rainbow Robotics were to change to Samsung Robotics, the market capitalization, which is currently around 3 trillion won, would likely exceed 10 trillion won. This is because among Samsung affiliates, there isn't a company with a market cap below 10 trillion won that represents the new growth engines. Since I've mentioned several times that robots could be responsible for Samsung's future, I believe that by next Christmas, we will all experience significant joy from Rainbow Robotics. SBB Tech has now been marked with a sticker, and its stock price has risen significantly in the short term. We have analyzed Rainbow Robotics together, and the momentum needs to continue.

Today, the market is showing significant volatility, and it seems we are experiencing a thematic market trend. In relation to this, I have brought one stock today, which is CIS. CIS is considered a key player in precursor materials and LFP batteries. It's important to note that this battery was originally not designed solely for automotive use; it is actually installed underground in general hospitals. In emergency rooms, if there is a power outage and essential medical equipment fails to operate, it can lead to serious consequences, especially for critically ill patients who rely on devices like ventilators. Therefore, LFP batteries are used as emergency power supply systems. However, since they are relatively inexpensive, they are now being used to replace ternary batteries, offering a price advantage of about 20% compared to ternary batteries.

We chose to adopt LP batteries because they are about 30% cheaper, but recently, LFP batteries have been recognized as having a lower risk of fire compared to the current ternary batteries. There are expectations for the government to announce some measures either this month or late next month regarding the electric vehicle phobia and the fire incidents related to electric vehicles. The risk of explosion is very low, especially unless there is sudden acceleration or hard braking, making the fire risk quite minimal. Particularly in the CIS region, there are companies developing dry equipment related to LFP batteries, and domestic battery manufacturers are also preparing for mass production of LFP batteries by 2026. While we may be about two years behind China in this regard, there is potential for significant orders, especially since CATL is recognized as a leading company in LFP battery technology, and they are also involved in electrode production.

A company that supplies manufacturing equipment is CIS, which recently merged with its subsidiary, C-Solid, specializing in solid-state battery technology. C-Solid is a company that mass-produces the key material, solid electrolyte, and also develops electrode process equipment for solid-state batteries. The merger with C-Solid in January indicates that CIS is aiming to accelerate its efforts in the solid-state battery sector. CIS has set a goal to start mass production of solid-state batteries by 2023, positioning itself as a major beneficiary in the solid-state battery market, as well as in lithium iron phosphate battery technology. These two technologies have recently emerged as alternatives in light of the electric vehicle fire incidents. Thus, CIS has two strong momentum factors driving its growth. Observing the strong movements in LG Energy Solutions yesterday, it appears that investments are flowing into the secondary battery sector.

Considering that there is potential for growth and that the challenges faced by electric vehicles are gradually being overcome, I believe there is still ample room for additional upward movement. With this perspective, I brought up today's topic. 

Today, Junoh Manager's highlighted stock is CIS LFP. Recently, there have been discussions about upgrading LFP, particularly regarding manganese. Additionally, it's worth noting that there is a solid-state battery theme associated with it. Currently, the secondary battery market is continuously evolving. After experiencing a brief cycle, we are now seeing advancements with the dream battery, solid-state lithium sulfide, which previously benefited companies like ISU Specialty Chemicals. Just yesterday, SDI and Ensol also made strides in this area. 

With this backdrop, LFP seems to be gaining traction again today. Therefore, CIS and LFP both have strong momentum, and considering that they supply electrode equipment to leading companies like CAT, I see a lot of positive aspects. The suggested buy price is 11,000 won.

I will try to catch it once, and I will set the first target price at 1,500 won, and I will mention the stop-loss price at 9,400 won. Now, today's notable stocks are the K market, which has become very unfavorable due to the current situation. To prepare for this, I will introduce two stocks. First, we have Cafe 24, an e-commerce startup solution company managed by Manager Young-min, and then we have Junno Manager, focusing on the secondary battery sector. Let's wait and see how the supply and demand in this area develops. This concludes today's notable stock briefing.

[일발장전] 카페24·씨아이에스 / 김영민·김준호의 일발장전 / 매일경제TV

매일경제TV는 매일경제신문은 물론 MBN, 매경닷컴 등 매경미디어그룹의 경제, 경영 금융, 증권 부동산, 창업 등 다양한 분야의 명품 콘텐츠를 제공함과 동시에 단순히 돈을 버는 것으로 끝나는 게 아니라 삶의 질을 높이는 방송이 될 것입니다. 

http://www.mktv.co.kr

mbnmoney2@gmail.com


[일발장전] 카페24·씨아이에스 / 김영민·김준호의 일발장전 / 매일경제TV

Scripts